WuXi Biologics (Cayman) (MEX:2269N) PE Ratio without NRI: 18.08 (As of Jun. 28, 2026) — 81% Below Median


MEX:2269N WuXi Biologics (Cayman) Inc MEX:2269N
99 GF Score
Price MXN62.53
GF Value MXN72.14
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) PE Ratio without NRI?

WuXi Biologics (Cayman) MEX:2269N 99 PE Ratio without NRI is 18.08 as of Jun. 28, 2026, which is 81% below its 10-year median of 97.39. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 268 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 52.99% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-28), WuXi Biologics (Cayman)'s share price is MXN62.53. WuXi Biologics (Cayman)'s EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was MXN3.44. Therefore, WuXi Biologics (Cayman)'s PE Ratio without NRI for today is 18.08.

During the past 12 years, WuXi Biologics (Cayman)'s highest PE Ratio without NRI was 292.80. The lowest was 8.85. And the median was 97.39.

WuXi Biologics (Cayman)'s EPS without NRI for the six months ended in Dec. 2025 was MXN1.97. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was MXN3.44.

As of today (2026-06-28), WuXi Biologics (Cayman)'s share price is MXN62.53. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MXN3.00. Therefore, WuXi Biologics (Cayman)'s PE Ratio (TTM) for today is 20.69.

Good Sign:

WuXi Biologics (Cayman) Inc stock PE Ratio (=25.79) is close to 1-year low of 24.06.

During the past years, WuXi Biologics (Cayman)'s highest PE Ratio (TTM) was 366.67. The lowest was 12.19. And the median was 102.00.

WuXi Biologics (Cayman)'s EPS (Diluted) for the six months ended in Dec. 2025 was MXN1.56. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was MXN3.00.

WuXi Biologics (Cayman)'s EPS (Basic) for the six months ended in Dec. 2025 was MXN1.64. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was MXN3.16.


WuXi Biologics (Cayman)  (MEX:2269N) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


WuXi Biologics (Cayman) PE Ratio without NRI Related Terms


WuXi Biologics (Cayman) PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) PE Ratio without NRI Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.82 47.42 25.54 14.72 21.40

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.54 At Loss 14.72 At Loss 21.40

MEX:2269N vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman) PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s PE Ratio without NRI falls into.


MEX:2269N
99GF Score
WuXi Biologics (Cayman) Inc MEX:2269N
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

WuXi Biologics (Cayman)'s PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=62.53/3.459
=18.08

WuXi Biologics (Cayman)'s Share Price of today is MXN62.53.
For company reported semi-annually, WuXi Biologics (Cayman)'s EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN3.44.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 18.08 mean?
WuXi Biologics (Cayman) (MEX:2269N) has a PE Ratio without NRI of 18.08 as of Jun. 28, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on WuXi Biologics (Cayman) and its competitors. This is 81% below median its historical median of 97.39. Over the past decade, WuXi Biologics (Cayman)'s PE Ratio without NRI has ranged from 8.85 to 292.80. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #126 out of 268 companies in the Biotechnology industry, placing it in the top 47%.
Is WuXi Biologics (Cayman)'s PE Ratio without NRI too high?
WuXi Biologics (Cayman)'s current PE Ratio without NRI of 18.08 is 81% below median its 10-year median of 97.39. Over the past 10 years, this metric has ranged from a low of 8.85 to a high of 292.80. The Biotechnology industry median PE Ratio without NRI is 25.14. WuXi Biologics (Cayman)'s value of 18.08 is 28.1% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #126 out of 268 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #126 out of 268 companies for PE Ratio without NRI. This puts WuXi Biologics (Cayman) in the upper half of its industry. The industry median PE Ratio without NRI is 25.14. WuXi Biologics (Cayman)'s value of 18.08 is 28.1% below this benchmark. Historically, WuXi Biologics (Cayman)'s own PE Ratio without NRI has ranged from 8.85 to 292.80 over the past decade. While the company's 10-year median is 97.39 vs. the industry median of 25.14, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.14, based on 268 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current PE Ratio without NRI of 18.08 is 28.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current PE Ratio without NRI is 18.08, which is 81% below median its own 10-year median of 97.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current PE Ratio without NRI of 18.08. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current PE Ratio without NRI is 18.08, which is 81% below median its 10-year median of 97.39 and 28.1% below the Biotechnology industry median of 25.14. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current PE Ratio without NRI is 18.08 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.

Key valuation signals for MEX:2269N:

  • PE Ratio without NRI: 18.08 (81% below median its 10-year median of 97.39)
  • GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
  • GF Score™: 99/100 with 3 warning signs
  • Industry Position: 28.1% below the Biotechnology median (#126 of 268)

No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score

Get the complete analysis for MEX:2269N

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.53
Price
MXN72.14
GF Value